A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Trial Profile

A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 25 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top